BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Alizyme PLC  (AZM.L) Release: Unaudited Preliminary Results For The Year Ended 31 December 2008


3/23/2009 2:54:26 PM

Cambridge UK, 23 March 2009: Alizyme plc (“Alizyme”) (LSE: AZM) today announces its unaudited preliminary results for the year ended 31 December 2008.

Highlights

Commercial

• COLAL-PRED® - Licence agreement with Norgine for Europe and other territories; €2.0 million upfront payment received

• Cetilistat - US$3.0 million milestone received from Takeda on entering Phase III development in Japan

Operational

Cetilistat (obesity and type 2 diabetes)

• Successful results of Phase II study in Japan in obese diabetic patients

• Phase III development commenced in Japan

• Protocols of all three studies in the Phase III obesity programme now agreed with FDA under SPA procedure

• FDA indicated a potential labelling for type 2 diabetes

COLAL-PRED® (ulcerative colitis)

• Headline results reported for EU Phase III clinical trial in approximately 800 patients with active moderate to severe ulcerative colitis

• Phase II clinical development commenced in the US by Prometheus

• Phase I clinical development commenced in Japan by TSD

ATL-104 (mucositis)

• Preparations for Phase II study in patients being treated for head and neck cancer ongoing

Renzapride (irritable bowel syndrome)

• Development by Alizyme discontinued

Financial

• Revenues of £1.9 million (2007: £0.01 million)

• Net loss after tax of £10.1 million (2007: £31.2 million)

• Cash, cash equivalents and money market investments of £2.2 million at 31 December 2008 (2007: £5.8 million)

• £10.0 million gross raised from shareholders in March 2008

• Cost saving measures introduced including reduction in headcount

Board changes

• Roger Lloyd and Richard de Souza appointed as Non-Executive Directors, with effect from 1 April 2009

• Bill Edge to resign as Non-Executive Director, with effect from 1 April 2009

• Richard Forrest resigned as Non-Executive Director on 31 August 2008

• David Campbell resigned as Finance Director and Company Secretary on 5 September 2008

• Nick Blech appointed as Company Secretary on 5 September 2008

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES